
    
      A randomized, double-blind, single migraine attack, placebo-controlled, parallel-group,
      multicenter study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan
      succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of
      menstrual migraine in women with dysmenorrhea (*TREXIMET)
    
  